This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression

Sponsored by National Institute of Mental Health (NIMH)

About this trial

Last updated 17 years ago

Study ID

950044

Status

Completed

Type

Observational

Placebo

No

Accepting

18-75 Years
All
All
All

Trial Timing

Ended 25 years ago

What is this trial about?

Major depression represents a major public health problem worldwide and in the U.S. Fifteen percent of the U.S. population has depression at some point in life (40 million individuals). The condition is more common in women, occurring at a female to male ratio of 5:2. Presently, 6-8% of all outpatients in primary care meet the diagnostic criteria for major depression. Fifteen percent of untreated patients with depression will commit suicide. Most of the people committing suicide are depressed. Researchers believe that by the year 2020 suicide will be the 10th most common cause of death in the U.S. In addition to mortality due to suicide, depression is also associated with other severe health conditions. Areas of the brain (hippocampus) begin to deteriorate, heart disease, and decreased bone mineral density (osteoporosis) are all associated with major depression. Researchers have believed for years that hormones controlled by the hypothalmus, pituitary gland, and adrenal gland (commonly referred to as the HPA axis or system) are in some way associated with psychiatric illnesses like depression. According to previous studies, researchers have theorized that increased activity of the HPA axis is associated with depressed patients with typical melancholic features. Melancholia refers to the feelings of anhedonia (absence of pleasure from activites that would normally be thought of as pleasurable), insomnia (inability to sleep), guilt, and psychomotor changes. On the other hand a decrease in activity of the HPA axis may be associated with the atypical features of depression. This study has already developed and refined studies that have improved the understanding of the HPA axis in healthy humans and depressed patients. Researchers have already identified and plan to continue identifying distinct subtypes of depressive disorders based on the activity of the HPA axis.

What are the Participation Requirements?

Patients with primary affective disorder (major depression), chronic fatigue syndrome, and
control subjects.

Psychiatric diagnosis will be made by means of the Structured Clinical Diagnosis for
DSM-III-R (SCID), performed by senior experienced clinicians.

Exclusion Criteria:

Subjects on chronic medications, which can not be washed out in one month.

Subjects with any serious medical illnesses which have been excluded.

Women who are pregnant, trying to become pregnant or sexually active and not using
effective contraception.

Patients with HIV-1 infection.

Patients on chronic lithium therapy.

Subjects unable to discontinue alcohol, tobacco, or illegal drugs.

Locations

Location

Status